Burak Okyar (@anarsiknotrofil) 's Twitter Profile
Burak Okyar

@anarsiknotrofil

(M.D. Rheumatology) Aşık @dr_ongun / Yolumu aydınlatan şey BİLİMİN ve SANATIN ışığıdır. Systemic sclerosis, SLE, Vasculitis, Sjögren's

ID: 756585035621425156

calendar_today22-07-2016 20:21:43

3,3K Tweet

521 Followers

1,1K Following

Alberto Giraldo (@alb_giraldo) 's Twitter Profile Photo

Granulomatosis with polyangiitis and microscopic polyangiitis treatment algorithm and suggested glucocorticoid tapering regime, from the 2025 British Society for Rheumatology management recommendations for #ANCA-associated #vasculitis 🔓 doi.org/10.1093/rheuma…

Granulomatosis with polyangiitis and microscopic polyangiitis treatment algorithm and suggested glucocorticoid tapering regime, from the 2025 British Society for Rheumatology management recommendations for #ANCA-associated #vasculitis

🔓 doi.org/10.1093/rheuma…
Adela Castro (@adelacastro222) 's Twitter Profile Photo

Pearls on EGPA: 1. GC are mainstay for mild dz 2. Organ threatening/relapsing➡️CYP (RTX alternative) 3. W/o organ threatening➡️ anti-IL-5/IL-5R. 4. IL5i are less effective for ENT 5. Consider sx for nasal polyps. #EULAR2025 Dr. John Cush

Pearls on EGPA:
1. GC are mainstay for mild
dz
2. Organ threatening/relapsing➡️CYP (RTX alternative)
3. W/o organ threatening➡️ anti-IL-5/IL-5R.
4. IL5i are less effective for ENT
5. Consider sx for nasal polyps.

#EULAR2025 <a href="/RheumNow/">Dr. John Cush</a>
Burak Okyar (@anarsiknotrofil) 's Twitter Profile Photo

Çok ama çok önemli bir sonuç bu. Yapay zekanın uzun dönem sonuçları bizim için ne ifade ediyor. Sanırım yaratıcılığımız ölüyor. Eğer tamamen biz yaratmıyorsak o zaman bunun değeri nedir?

Burak Okyar (@anarsiknotrofil) 's Twitter Profile Photo

An excellent compilation. We are so focused on pharmacotherapy that we lose sight of evaluating the patient as a whole. A wonderful compilation. ⬇️⬇️⬇️⬇️⬇️⬇️⬇️⬇️⬇️

Rheuma Doc (@lastmanstand85) 's Twitter Profile Photo

Ozoralizumab a next-generation anti-TNF NANOBODY. Primary objective was to evaluate the efficacy of OZR in patients with RA. 30mg ⬇️ significant reductions in DAS28 at 52W & ⬇️ in mean RF & CCP titres over 52W. Treatment effective regardless of titres #Rheumatology #MedTwitter

Ozoralizumab a next-generation anti-TNF NANOBODY. Primary objective was to evaluate the efficacy of OZR in patients with 
RA. 30mg ⬇️ significant reductions in DAS28 at 52W &amp; ⬇️ in mean RF &amp; CCP titres over 52W. Treatment effective regardless of titres 
#Rheumatology #MedTwitter